Introduction
============

*Pseudomonas aeruginosa* is a common clinical cause of gram-negative bacterial, nosocomial infections ([@b1-etm-0-0-5727]), and causes serious infections in neutropenic and immunocompromised patients ([@b2-etm-0-0-5727]). Within intensive care units, *P. aeruginosa* has become the most common gram-negative bacterial species associated with severe hospital-acquired infections ([@b2-etm-0-0-5727],[@b3-etm-0-0-5727]). At present, the worldwide morbidity and mortality rates of *P. aeruginosa* are 18 and 61% respectively ([@b1-etm-0-0-5727]--[@b3-etm-0-0-5727]). The treatment of *P. aeruginosa* infections in a clinical setting remains a notable challenge. The capacity of patients to ingest the appropriate antibiotics in a timely manner positively affects prognosis of severe pseudomonas-infection ([@b4-etm-0-0-5727]). As such, this variable serves as an important controllable risk factor ([@b4-etm-0-0-5727],[@b5-etm-0-0-5727]). Clinical infection with *P. aeruginosa* may be associated with an increase in 30-day mortality in patients. Treatment with appropriate antibiotics, such as β-lactam and fluoroquinolone, is associated with the prognosis ([@b6-etm-0-0-5727]). However, the use of appropriate antibiotic treatment does not consistently show satisfactory effects on patients ([@b7-etm-0-0-5727],[@b8-etm-0-0-5727]). It has previously been suggested that the inappropriate use of antibiotics in the treatment of *P. aeruginosa* bacteraemia may be minimised by a combination antibiotic regimen, in which the sensitivity of results is determined following treatment ([@b8-etm-0-0-5727]). Inappropriate use of empirical antibiotic therapy has been identified as an independent contributor to the high hospital mortality rate of *P. aeruginosa* bacteraemia ([@b8-etm-0-0-5727],[@b9-etm-0-0-5727]). Combination therapy has been shown to yield improved results compared with single treatment of *P. aeruginosa* bacteraemia ([@b6-etm-0-0-5727],[@b9-etm-0-0-5727]), and combination empirical antimicrobial therapy directed against gram-negative bacteria may be a more appropriate treatment approach than monotherapy ([@b10-etm-0-0-5727]). Despite the merits of relevant studies on empirical combination therapy, it is still unclear whether the use of combination therapy is more effective than monotherapy in treating *P. aeruginosa* infection ([@b10-etm-0-0-5727]--[@b18-etm-0-0-5727]). In the present study a meta-analysis was conducted and the mortality of patients treated with either combination therapy or the appropriate monotherapy for *P. aeruginosa* bacteraemia was compared and evaluated.

Materials and methods
=====================

### Search terms

Several electronic bibliographic databases were searched including the Chinese Biomedical Literature *Database* (Wanfang, China), China Academic Journals Full-text *database*, Cochrane Library, PubMed and Embase for the identification of relevant studies (as of April 2017). The included search terms were: *Pseudomonas aeruginosa*, bacteremia, monotherapy, combination therapy, antibiotic, mortality and outcome. The databases were searched manually to identify potentially relevant studies. The reference lists of all retrieved articles were also searched to find research that could qualify for the study. Only articles written in Chinese or English were considered; articles written in German, French, Spanish, Italian and Greek were not evaluated. Ultimately, all included papers were written in English. The study inclusion criteria were as follows: i) The study compared the efficacy of monotherapy and combination therapy; ii) retrospective and prospective studies; iii) the treatments discussed in the study included at least one antibiotic agent, which was reported following sustained or initial antibacterial spectrum results ([@b8-etm-0-0-5727]); and iv) the study results included data on mortality.

### Study selection

Two experienced independent reviewers (S-YT and S-WZ) subsequently read through the results and decided which studies were appropriate to be included in the meta-analysis ([@b5-etm-0-0-5727],[@b10-etm-0-0-5727]--[@b25-etm-0-0-5727]). Any differences in opinion between the two reviewers were resolved by discussion until a consensus was reached. The following data was extracted from each qualified study: Name of first author, type of publication, type of study design, gender and age of patients, sample size, length of hospital stay, type of treatment, type and choice of drugs, mortality, outcomes, number of different populations, and odds ratio (OR) and 95% confidence interval (CI) results. The possible risk estimates were extracted and adjusted using hybrid variables.

### Quality assessment

The selected studies were evaluated using a system based on the cohort study using the Newcastle-Ottawa scale ([@b26-etm-0-0-5727]), which provides a score for studies between 1--9 'stars'. Three aspects were used to assess the quality of studies: i) Choice of learning study, ii) organisational evaluation and iii) evaluation of comparison results. As there is dispute over the number of stars that must be used as an indicator of high-quality studies ([@b27-etm-0-0-5727]--[@b33-etm-0-0-5727]), the included studies were compared; studies that received ≥7 stars ([@b7-etm-0-0-5727],[@b8-etm-0-0-5727],[@b9-etm-0-0-5727]) were defined as high-quality studies, and those that scored ≤6 were not.

### Statistical methods

Statistical analysis was conducted using Stata version 12.0 software (StataCorp LP, College Station, TX, USA). ORs with 95% CIs were extracted from studies to evaluate the outcomes of mortality. Cochrane\'s X2 Q and I^2^ tests were employed to assess the differences in data from different studies. Stochastic models were applied to heterogeneity studies (P\<0.1 or I^2^\>50%) ([@b34-etm-0-0-5727],[@b35-etm-0-0-5727]). The Mantel-Haenszel fixed-effect model was used to calculate pools or studies when P\>0.10 and I^2^≤50%; otherwise, the Dersimonian and Laird\'s random-effects model was used to combine results ([@b36-etm-0-0-5727]). A sensitivity analysis was also conducted to examine the effects of each study on mixed outcomes. To establish the effects of clinical heterogeneity on meta-analysis, a subgroup analysis was conducted based on study characteristics. Egger\'s precision-weighted linear regression tests and funnel charts were used to assess potential publication bias ([@b37-etm-0-0-5727]). When a study demonstrated potential publication bias, the nonparametric correction and filling method was applied. The filling method evaluates the possibility of 'missing' studies that may exist and recalculates the pool or merges them ([@b34-etm-0-0-5727],[@b35-etm-0-0-5727]). The results of the meta-analysis were stratified by types of study and treatment. P\<0.05 was considered to indicate a statistically significant difference, unless otherwise stated.

Results
=======

### Search results

[Fig. 1](#f1-etm-0-0-5727){ref-type="fig"} demonstrates the process of study selection and the number of studies excluded at each stage. In the initial search 115 studies were identified, and following a review of the titles, 31 studies were considered for inclusion. The summaries of those 31 studies were reviewed and all studies that were considered eligible were retrieved. Among these studies 14 were excluded for the following reasons: 3 studies did not compare monotherapy and combination therapy; 4 studies did not include mortality rate in the assessment of results; 2 were excluded because patient infection did not cause bacteraemia; and 5 were excluded as data could not be extracted. Therefore, following the screening process 17 studies qualified ([@b5-etm-0-0-5727],[@b10-etm-0-0-5727]--[@b25-etm-0-0-5727]) and were included in the meta-analysis; they covered a total of 2,504 patients with cases of *P. aeruginosa* bacteraemia.

### Study characteristics

Within the qualified studies, 14 were retrospective studies and 3 were prospective studies ([Fig. 2](#f2-etm-0-0-5727){ref-type="fig"}). There were 5 studies that reported outcomes of empirical treatment and 12 studies that reported outcomes of definitive treatment ([Fig. 3](#f3-etm-0-0-5727){ref-type="fig"}). There were 4 studies conducted in the United States, 7 in Europe, 6 in Asia and 1 was conducted in the United States and Singapore ([Table I](#tI-etm-0-0-5727){ref-type="table"}). According to the Newcastle-Ottawa Scale, 16 of the included studies scored \>6 and were rated as good or excellent quality ([Table I](#tI-etm-0-0-5727){ref-type="table"}).

### Mortality

There were 8 studies that used survival for 30 days, 1 that used survival for 14 days and 1 that used survival for 10 days as the desired outcome of the study. There were 7 studies that considered overall survival as the desired outcome. In terms of mortality, significant difference was observed between patients who received definitive treatment compared with those who received the appropriate empirical treatment (OR=0.81, 95% CI=0.61--1.08; [Fig. 3](#f3-etm-0-0-5727){ref-type="fig"}).

### Publication bias

Considering the observed heterogeneity (P=0.035; I^2^=42.1%) of the 17 included studies, a random-effects model was used for their analysis ([Fig. 2](#f2-etm-0-0-5727){ref-type="fig"}). The following factors were considered: Source of patients, types of study design (OR=0.85, 95% CI=0.60--1.19, P=0.034), types of treatment (OR=0.72, 95% CI=0.42--1.23, P=0.019), study population (OR=0.74, 95% CI=0.41--1.33, P=0.036), literature quality score (OR=0.67, 95% CI=0.45--1.00, P=0.082), and mortality of subgroup stratification analysis (OR=1.17, 95% CI=0.75--1.85, P=0.117; [Table II](#tII-etm-0-0-5727){ref-type="table"}). Retrospective and prospective studies were significantly different in subgroup analysis. Visual inspection of the funnel plots revealed asymmetry among studies ([Fig. 4](#f4-etm-0-0-5727){ref-type="fig"}). Consolidation effect was assessed to review the influence results for each study ([Fig. 5](#f5-etm-0-0-5727){ref-type="fig"}). Begger\'s and Egger\'s tests were conducted to determine publication bias ([Figs. 6](#f6-etm-0-0-5727){ref-type="fig"} and [7](#f7-etm-0-0-5727){ref-type="fig"}) and L\'Abbé analysis was performed to assess the heterogeneity of effect sizes, which revealed no marked heterogeneity ([Fig. 8](#f8-etm-0-0-5727){ref-type="fig"}). The Z-value and P-value of Begger\'s test reached 0.21 and 0.805, respectively, and the t-value and P-value of Egger\'s test totalled −0.24 and 0.815 respectively. Both P-values of Egger\'s test and Begger\'s test were \>0.05. Therefore, these results indicated that there was no compelling evidence to affirm that results obtained were free from published publication bias.

### Subgroup and sensitivity analysis

[Table II](#tII-etm-0-0-5727){ref-type="table"} demonstrates the stratified analysis designed to focus OR of 0.85 (95% CI=0.60--1.19) for 14 retrospective cohorts and the 12 studies with specific definitive therapy OR of 0.88 (95% CI=0.62--1.24). A strong correlation was identified in studies conducted in Asian countries, and study quality and mortality did not significantly affect the results ([Figs. 9](#f9-etm-0-0-5727){ref-type="fig"}--[11](#f11-etm-0-0-5727){ref-type="fig"}).

The contribution of studies to overall prevalence and 95% CIs was evaluated. In sensitivity analyses, surveyed time strip was omitted and then results were combined with a single dataset on pooled ORs. Corresponding pooled ORs did not change significantly from 0.67 (95% CI=0.45--1.00) to 0.85 (95% CI=0.60--1.19). Therefore, the results obtained were considered statistically strong.

### Cumulative meta-analysis

Heterogeneity inspection was conducted initially and the effects, combined effects and their corresponding CI were evaluated to obtain the Q statistic and its corresponding P-value. Heterogeneity=27.63 (degree of freedom=16), P=0.035 and I^2^=42.1%. Given that no clear heterogeneity was observed among studies, cumulative analysis was performed using a random-effects model. Fixed number of years and sample size were considered for cumulative meta-analysis. Organised in chronological order, OR value and 95% CI were stable and demonstrated good change trend, aside from the study by Bliziotis *et al* ([@b11-etm-0-0-5727]) ([Fig. 12](#f12-etm-0-0-5727){ref-type="fig"}). Based on sample size order following accumulation, when a large sample was included, the range of OR values and 95% CI (0.89; 0.76--1.04) was decreased ([Fig. 13](#f13-etm-0-0-5727){ref-type="fig"}).

Discussion
==========

The present study consisted of a meta-analysis that compared the effects of using either a combination of antibiotics or a single antibiotic for the treatment of *P. aeruginosa* bacteraemia. A total of 17 studies were systematically reviewed and compared. The antibiotic and appropriate empirical treatments used were determined by extracting data from the studies, and the patients\' all-cause mortality associated with *P. aeruginosa* bacteraemia was analysed. No significant differences were identified between monotherapy and combination therapy in regards to mortality. Therefore, definite combination therapy and appropriate combination of therapies failed to independently provide additional benefits for patient treatment. However, in the subgroup analysis process significant differences were observed in types of study design and types of treatment. In particular, the use of β-lactam and cephalosporin antibiotics as an empirical treatment were able to significantly reduce the mortality rate of patients.

In clinical treatment, patient mortality associated with *P. aeruginosa* bacteraemia remains high (61%) despite the progress of antibiotic therapy; thus, an improved treatment approach is required ([@b38-etm-0-0-5727]). Bliziotis *et al* ([@b11-etm-0-0-5727]) reported that combination therapy was superior to monotherapy in treating patients with *P. aeruginosa* bacteraemia; however, 81% of patients (25/31) who received monotherapy only received β-lactam, which cannot be considered the optimum monotherapy owing to the increased mortality rate associated with this drug compared with other monotherapies ([@b20-etm-0-0-5727],[@b21-etm-0-0-5727],[@b39-etm-0-0-5727]). Micek *et al* ([@b5-etm-0-0-5727]) observed that compared with single antibiotics, combination therapy yielded improved effects. However, given the open clinical design of the study, patients in a single-treatment group may be more likely to receive additional antibiotics and were therefore considered treatment failures in these studies. The number of patients included in meta-analysed subgroups were assessed in each randomised controlled study. As such, the baseline comparable *P. aeruginosa* bacteraemia infection between monotherapy and combination therapy groups was not established. Confounding factors in the remaining studies may be attributed to lack of randomisation, thus leading to incorrect conclusions ([@b39-etm-0-0-5727]). Another previous meta-analysis also performed a similar comparison by using β-lactam monotherapy and a combination of β-lactam and aminoglycosides on immunoreactive sepsis patients ([@b6-etm-0-0-5727]); the results revealed that association of combination therapy with single treatments was not advantageous in all-cause mortality or other treatment failure in patient subgroups with *P. aeruginosa* bacteraemia infection. By contrast, another study focused on analysis of patients with gram-negative bacteraemia. Following subgroup analysis of the results it was identified that combination antibiotic treatment led to a reduction in the mortality rates of *P. aeruginosa* bacteraemia compared with monotherapy, however these results were not representative of all gram-negative bacteraemia studied ([@b6-etm-0-0-5727],[@b40-etm-0-0-5727]). As previously revealed, inferior quality and heterogeneity of studies considered in these meta-analyses resulted in unreliable clinical data. Differences among patients were also notable and results often differed ([@b39-etm-0-0-5727]). A recent meta-analysis studied the effects of carbapenem-resistant *P. aeruginosa* bacteraemia on mortality ([@b41-etm-0-0-5727]). Another meta-analysis study on the benefits of clinical treatment was conducted through the use of an empirical combination therapy using β-lactam combined with an aminoglycoside or fluoroquinolones and β-lactam monotherapy for *P. aeruginosa* infection ([@b42-etm-0-0-5727]). In a subgroup analysis (5 studies) of *P. aeruginosa* bacteraemia, the results of the clinical treatment demonstrated no significant difference in mortality between patients treated with monotherapy and combination therapy. According to the above variances, a meta-analysis was conducted in the present study; to the best of our knowledge *P. aeruginosa* bacteraemia, although common in patients with bacteraemia, is not very common in clinical settings. Thus, the sample size was limited. The present review also indicated limited clinical reviews and prospective study design. Owing to these limitations, baseline comparison of *P. aeruginosa* bacteraemia infection between monotherapy and combination therapy was not established. Therefore, difficulty arose from completing large randomised prospective clinical trials. Patient complications also differed; multidrug-resistant (MDR) *P. aeruginosa* strains became increasingly common and varied in terms of selection of drug types. Therefore, studies were not analysed according to specific antibiotics, as the present meta-analysis was performed with different antimicrobial therapies. In several studies ([@b13-etm-0-0-5727],[@b14-etm-0-0-5727],[@b16-etm-0-0-5727],[@b18-etm-0-0-5727],[@b24-etm-0-0-5727]), comparisons between selected empirical antibiotic therapy and definitive treatment were retrospectively analysed. Other studies rated the Chronic Health Evaluation score of in-patients ([@b12-etm-0-0-5727],[@b16-etm-0-0-5727],[@b23-etm-0-0-5727],[@b25-etm-0-0-5727]). Appropriate treatment involves antibiotic isolation therapy for certain *in-vitro*-sensitive agents, especially for aminoglycoside antibiotic-sensitive patients ([@b19-etm-0-0-5727],[@b35-etm-0-0-5727]). The use of monotherapy for treatment of *P. aeruginosa* bacteraemia was considered inappropriate in previous studies comparing single and combination therapies ([@b10-etm-0-0-5727],[@b15-etm-0-0-5727]). Some meta-analyses conducted from the perspective of treatment and mortality compared effectiveness of combination antibiotics and monotherapy in clinical treatment of *P. aeruginosa* ([@b43-etm-0-0-5727]). The present meta-analysis did not focus on survival rate and quality evaluation. A limitation of the present study was the lack of scope in comparing study type and treatment selection. For patients with MDR bacterial infection and *P. aeruginosa*, providing combination antibiotic therapy may improve results as this method increases possibility of appropriate treatment ([@b42-etm-0-0-5727]). In addition to the appropriate choice of empirical treatment, the severity of complications is another risk factor that may also affect mortality rate of patients during bacterial infections including *P. aeruginosa* ([@b42-etm-0-0-5727]). Combination therapy with *P. aeruginosa* also presents potential risks, particularly drug toxicities, including aminoglycoside antibiotics associated with human renal toxicity ([@b6-etm-0-0-5727]). Likelihood of repeated infection in clinical patients and the increased cost must also be considered in comparing combination therapy with monotherapy.

Limitations of meta-analysis conducted in the present study were recognised. The quality of included studies may be questioned due to incomplete or inaccurate data collection. The research on adjustment of these confusing factors is limited and therefore cannot be studied for potential co-founder influence, including severity of disease and potential for concurrent conditions. The funnel plot and Egger\'s test indicated a possibility of publication bias, however trim-and-fill analysis revealed that results did not change. Only sensitivity analysis and evaluation, patient source, study types, treatment options and mortality were analysed. Finally, only studies published in English were included. This may introduce language bias, possibly resulting in incomplete study and thus reducing accuracy of analysis of the treatment results.

In conclusion, the results demonstrated no significant difference in mortality between patients administered with combined antibiotic or monotherapy treatment against *P. aeruginosa* bacteraemia. Combination therapy may be associated with clinical treatment of monotherapy, particularly when used in empirical therapy. These results were mainly obtained from retrospective and secondary studies. Thus, no definite conclusions may be drawn regarding combination of effectiveness and single therapy in patients and groups. Relevant evidence obtained was also limited. Therefore, large-scale and well-designed studies must be developed and conducted on credibility of treatment mechanisms to determine whether a causal association exists.
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###### 

Characteristics of the eligible studies included in the meta-analysis of monotherapy vs. combination therapy for *Pseudomonas aeruginosa* bacteraemia.

                                                                                                                        Drugs                                                                                                                                                                                                                         Mortality (mortality cases/total)                                                                                                                 
  ---------------------------- --------------- ------------------------ --------------- ------------------------------- ----------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------- ----------------------------------- -------- -------- --- --------------------------------------------------------------------------------------- -----------------------
  Bowers *et al*, 2013         Retrospective   2002--2011               USA/Singapore   Appropriate empirical therapy   More than one antipseudomonal agent                                                                                           An antipseudomonal antimicrobial agent                                                          Mortality                           30/82    82/286   9   Diabetes mellitus, liver cirrhosis, respiratory conditions, renal disease               ([@b12-etm-0-0-5727])
  Park *et al*, 2012           Retrospective   1997--2011               South Korea     Appropriate empirical therapy   A β-Lactam antibiotic and either an aminoglycoside or ciprofloxacin                                                           A β-lactam or ciprofloxacin                                                                     28 days                             10/33    17/32    9   APACHE II score, liver cirrhosis, immunosuppression, hematologic malignancy             ([@b23-etm-0-0-5727])
  Bliziotis *et al*, 2011      Retrospective   2001--2007               Greece/Italy    Definitive treatment            A β-Lactam and an aminoglycoside or a quinolone                                                                               β-Lactam antibiotic                                                                             Mortality                           6/31     8/19     9   AIDS, HIV, solid tumor, respiratory dysfunction, cardiovascular dysfunction             ([@b11-etm-0-0-5727])
  Micek *et al*, 2005          Retrospective   1997--2002               USA             Definitive treatment            A β-lactam and an aminoglycoside                                                                                              A β-lactam or ciprofloxacin                                                                     Mortality                           13/59    16/106   8   APR-DRG score, shock                                                                    ([@b5-etm-0-0-5727])
  Chamot *et al*, 2003         Retrospective   1988--1998               Switzerland     Definitive treatment            A β-lactam and an administration of an administration of an aminoglycoside together with ciprofloxacin                        A β-lactam or aminoglycoside or fluoroquinolones                                                30 days                             10/46    9/33     8   Simple sepsis, severe sepsis, shock                                                     ([@b10-etm-0-0-5727])
  Siegman-Igra *et al*, 1998   Retrospective   1990--1992               Israel          Definitive treatment            A fluoroquinolone, a third-generation cephalosporin, cilastatin or a ureidopenicillin in combination with an aminoglycoside   A fluoroquinolone, a third-generation a third-generation cephalosporin or imipenem/cilastatin   Overall mortality                     7/15     7/42   7   Malignancy, neutropenia                                                                 ([@b15-etm-0-0-5727])
  Kuikka and Valtonen, 1998    Retrospective   1976--1982, 1992--1996   Finland         Definitive treatment            A β-lactam and either an aminoglycoside or quinolone                                                                          β-lactam or ciprofloxacin                                                                       30 days                             11/41    7/32     7   Leukopenia, cholelithiasis, COPD, alcohol abuse, indwelling urinary catheter            ([@b21-etm-0-0-5727])
  Mendelson *et al*, 1994      Retrospective   1978--1992               USA             Definitive treatment            Ceftazidime, piperacillin, cefoperazone, aztreonam and an aminoglycoside (gentamicin, tobramycin)                             Ceftazidime, piperacillin, cefoperazone, aztreonam or ciprofloxacin                             Mortality                             4/15     4/9    6   HIV, cryptococcal meningitis, pneumocystis pneumonia                                    ([@b22-etm-0-0-5727])
  Leibovici *et al*, 1997      Prospective     1988--1995               Israel          Definitive treatment            A β-lactam and an aminoglycoside                                                                                              A β-lactam                                                                                      Mortality                           16/77    20/95    7   Septic shock, malignancy, neutropenia, congestive heart failure                         ([@b20-etm-0-0-5727])
  Hilf *et al*, 1989           Prospective     1982--1986               USA             Definitive treatment            An aminoglycoside and an antipseudomonal β-lactam                                                                             Antipseudomonal antibiotics including aminoglycoside, β-lactam                                  10 days                             38/143   20/43    7   Malignancy, neutropenia, pneumonia, MODS                                                ([@b19-etm-0-0-5727])
  Peña *et al*, 2013           Prospective     2010--2011               Spain           Definitive treatment            A β-lactam + aminoglycoside, fluoroquinolones or colistin                                                                     A β-lactam or aminoglycoside or fluoroquinolones or colistin                                    30 days                             13/71    70/339   9   Hepatobiliary HIV/AIDS, diabetes mellitus, MODS                                         ([@b18-etm-0-0-5727])
  Kim *et al*, 2014            Retrospective   2010--2012               South Korea     Definitive treatment            A β-lactam and aminoglycosides fluoroquinolones, colistin and fluoroquinolones or aminoglycoside                              A β-lactam, fluoroquinolones, colistin or aminoglycosides                                       14 days                             6/42     32/141   9   Diabetes mellitus, liver cirrhosis, malignancy, hypertension                            ([@b16-etm-0-0-5727])
  Samonis *et al*, 2014        Retrospective   2004--2010               Greece          Definitive treatment            A β-lactam + aminoglycoside/fluoroquinolone/colistin or colistin + other                                                      A β-Lactam or fluoroquinolone, colistin                                                         Mortality                           12/37    14/45    8   Chronic lung disease, diabetes mellitus, chronic heart disease, chronic renal disease   ([@b17-etm-0-0-5727])
  Tan SH *et al*, 2014         Retrospective   2007--2008               Singapore       Definitive treatment            A β-lactam + aminoglycosides or ciprofloxacin                                                                                 A β-Lactam or aminoglycosides or ciprofloxacin                                                  30 days                               2/14   17/77    9   SAPS II score, HIV/AIDS, diabetes mellitus, cardiovascular dysfunction                  ([@b25-etm-0-0-5727])
  Deconinck *et al*, 2017      Retrospective   1994--2014               France          Appropriate empirical therapy   A β-Lactam + an aminoglycoside, aquinolone or colistin                                                                        A β-Lactam, aminoglycoside, fluoroquinolone or colistin                                         30 days                             32/85      7/15   9   Shock, SAPS II, multiresistant strains                                                  ([@b13-etm-0-0-5727])
  Paulsson *et al*, 2017       Retrospective   2005--2010               Sweden          Appropriate empirical therapy   Carbapenem, cefotaxime + tobramycin or piperacillin                                                                           Cefotaxime, cefuroxime or piperacillin                                                          30 days                             16/79    12/56    7   COPD, neurological paresis, diabetes mellitus, heart disorder, AIDS                     ([@b14-etm-0-0-5727])
  Yoon                         Retrospective   2012--2015               South Korea     Appropriate empirical therapy   A β-Lactam and an aminoglycoside or a quinolone                                                                               A β-lactam or                                                                                   30 days                             25/85    84/179   9   Septic shock, neutropenia, Pitt bacteraemia score                                       ([@b24-etm-0-0-5727])

Study quality was evaluated according to the Newcastle-Ottawa scale ([@b26-etm-0-0-5727]). AIDS, acquired immunodeficiency syndrome; HIV, human immunodeficiency virus; SAPS II, simplified acute physiology score; COPD, chronic obstructive pulmonary disease; APR-DRG, all patient refined-diagnosis related group; MODS, multiple organ dysfunction syndrome.

###### 

Stratified analyses of pooled ORs.

                                                                                                                  Heterogeneity test          
  ------------------ ------------------------------------------------------------------ ----- ------------------- -------------------- ------ --------------------------------------------------------------------------------------------------------------------------------------------------------------------
  All studies        --                                                                 17    0.81 (0.61--1.08)   0.035                42.1   ([@b5-etm-0-0-5727],[@b10-etm-0-0-5727]--[@b18-etm-0-0-5727],[@b31-etm-0-0-5727]--[@b37-etm-0-0-5727])
  Study population   Asian                                                                6   0.74 (0.41, 1.33)   0.036                58.0   ([@b15-etm-0-0-5727],[@b16-etm-0-0-5727],[@b32-etm-0-0-5727],[@b35-etm-0-0-5727]--[@b37-etm-0-0-5727])
                     Non-Asian^[a](#tfn2-etm-0-0-5727){ref-type="table-fn"}^            11    0.88 (0.65, 1.20)   0.196                26.0   ([@b5-etm-0-0-5727],[@b10-etm-0-0-5727]--[@b14-etm-0-0-5727],[@b17-etm-0-0-5727],[@b18-etm-0-0-5727],[@b31-etm-0-0-5727],[@b33-etm-0-0-5727],[@b34-etm-0-0-5727])
  Study design       Prospective cohort^[a](#tfn2-etm-0-0-5727){ref-type="table-fn"}^     3   0.71 (0.42, 1.18)   0.193                39.2   ([@b18-etm-0-0-5727],[@b31-etm-0-0-5727],[@b32-etm-0-0-5727])
                     Retrospective cohort                                               14    0.85 (0.60, 1.19)   0.034                45.1   ([@b5-etm-0-0-5727],[@b10-etm-0-0-5727]--[@b17-etm-0-0-5727],[@b33-etm-0-0-5727]--[@b37-etm-0-0-5727])
  Therapy type       Definitive therapy                                                 12    0.88 (0.62, 1.24)   0.173                27.7   ([@b5-etm-0-0-5727],[@b10-etm-0-0-5727],[@b11-etm-0-0-5727],[@b15-etm-0-0-5727]--[@b18-etm-0-0-5727],[@b32-etm-0-0-5727]--[@b35-etm-0-0-5727],[@b37-etm-0-0-5727])
                     Appropriate empirical therapy                                        5   0.72 (0.42, 1.23)   0.019                65.9   ([@b12-etm-0-0-5727]--[@b14-etm-0-0-5727],[@b31-etm-0-0-5727],[@b36-etm-0-0-5727])
  Study quality      9 stars                                                              8   0.67 (0.45, 1.00)   0.082                44.5   ([@b11-etm-0-0-5727]--[@b13-etm-0-0-5727],[@b16-etm-0-0-5727],[@b18-etm-0-0-5727],[@b35-etm-0-0-5727]--[@b37-etm-0-0-5727])
                     8 stars                                                              3   1.15 (0.68, 1.95)   0.515                --     ([@b5-etm-0-0-5727],[@b10-etm-0-0-5727],[@b17-etm-0-0-5727])
                     7 stars                                                              5   1.03 (0.53, 1.99)   0.029                63.0   ([@b14-etm-0-0-5727],[@b15-etm-0-0-5727],[@b31-etm-0-0-5727]--[@b33-etm-0-0-5727])
                     6 stars^[b](#tfn3-etm-0-0-5727){ref-type="table-fn"}^                1   0.45 (0.08, 2.60)   --                   --     ([@b34-etm-0-0-5727])
  Outcome            Overall mortality                                                    7   1.17 (0.75, 1.85)   0.117                41.1   ([@b5-etm-0-0-5727],[@b11-etm-0-0-5727],[@b12-etm-0-0-5727],[@b14-etm-0-0-5727],[@b15-etm-0-0-5727],[@b17-etm-0-0-5727],[@b34-etm-0-0-5727])
                     30-day mortality                                                     8   0.67 (0.49, 0.90)   0.611                  0    ([@b10-etm-0-0-5727],[@b13-etm-0-0-5727],[@b14-etm-0-0-5727],[@b18-etm-0-0-5727],[@b33-etm-0-0-5727],[@b35-etm-0-0-5727]--[@b37-etm-0-0-5727])
                     14-day mortality^[b](#tfn3-etm-0-0-5727){ref-type="table-fn"}^       1   0.57 (0.22, 1.47)   --                   --     ([@b16-etm-0-0-5727])
                     10-day mortality^[b](#tfn3-etm-0-0-5727){ref-type="table-fn"}^       1   0.42 (0.21, 0.84)   --                   --     ([@b31-etm-0-0-5727])

The fixed-effect model was used to calculate the pooled OR if P\>0.10 and I^2^≤50%; otherwise, the random-effect model was used to merge the results.

Pooled ORs were not provided when stratified analysis only included one or two studies. CI, confidence interval; OR, odds ratio.

[^1]: Contributed equally
